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Abstract Whether quantitative, two-dimensional, and three-
dimensional plaquemeasurements by intravascular ultrasound
with radiofrequency backscatter (IVUS/VH) are different
between intermediate lesions with or without major adverse
cardiovascular events (MACE) is unknown. IVUS/VH-derived
parameters were compared in 60 patients with an intermediate
coronary lesion (40–70 %) between lesions that did or did not
result in MACE over 12 months. IVUS/VH measurements
were done at the site of the minimal lumen area (MLA) and
on a per-plaque basis, defined by 40 % plaque burden. Pre-
specified, adjudicated MACE events occurred in 5 of 60
patients (8.3 %). MACE lesions had larger plaque burden
(65 % vs. 53 %, p=0.004), less dense calcium (6.6 % vs.
14.7 %, p=0.05), and more non-calcified plaque, mostly
fibrofatty kind (17.6 % vs. 10 %, p=0.02). Intermediate coro-
nary lesions associated with MACE at 12 months have more
plaque, less dense calcium, and more non-calcified plaque,
particularly fibrofatty tissue by IVUS/VH.
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Introduction
Atherosclerotic coronary artery disease (CAD) remains the
leading cause of morbidity and mortality in the USA, and
accordingly, approximately 1,350,000 patients suffer an
acute coronary syndrome (ACS) each year [1]. Moreover,
approximately 20 % of patients who suffered an initial event
will have a recurrent event within a year [2, 3].
Atherosclerosis progresses through a series of molecular
and cellular processes resulting in a series of geometrical and
compositional changes that can be detected by imaging mo-
dalities [4]. The “vulnerable plaque” paradigm hypothesizes
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that certain histopathological features of coronary atheroscle-
rotic plaques are associated with plaque rupture [5] and in-
clude mild–moderate luminal stenosis, large plaque burden,
more lipid pool and lipid-rich necrotic core, more inflamma-
tion, and less calcification. Moreover, thin-cap fibroatheromas
(TCFA) are the most predominant morphology found in au-
topsy series of ruptured plaques [6–13]. However, prospective
validation of such features in vivo has been challenging in the
absence of a reliable imaging method.
Recently, gray-scale intravascular ultrasound (IVUS) and
IVUS with radiofrequency backscatter analysis (IVUS/VH)
have been utilized as an invasive means of visualizing human
coronary arterial plaques in vivo [14]. Several retrospective
IVUS/VH studies demonstrated that plaques associated with
events had larger plaque burden, more necrotic core, less
calcification, and the presence of IVUS/VH defined TCFA
(VH-TCFA) [15]. Furthermore, a recent, large, prospective
study (PROSPECT: “A prospective natural-history study of
coronary atherosclerosis”) utilizing three-vessel IVUS/VH
based on cross-sectional luminal analysis showed that mini-
mal lumen area (MLA) plaque burden and the presence of
VH-TCFAwere independent predictors of major adverse car-
diovascular events (MACE) [16]. However, features of non-
obstructive plaques that resulted in MACE prospectively over
a 12-month period have not been investigated before in three-
dimension (3D) on a per-plaque basis. Accordingly, we hy-
pothesized that plaques associated with MACE over a 12-
month period will have larger plaque burden, more non-
calcified plaque, more necrotic core, and less dense calcium
compared to lesions that were not associated with MACE,
based on 3D IVUS/VH measurements on a per-plaque basis.
Methods
General Study Design
The ATLANTA (Assessment of Tissue characteristics, Lesion
morphology and hemodynamics by Angiography with fraction-
al flow reserve, intravascular ultrasound and virtual histology
and Non-invasive computed Tomography in Atherosclerotic
plaques) study was a prospective, single-center, investigator-
initiated study approved by the Institutional Review Board of
Piedmont Healthcare. The overall study design has been pub-
lished previously [15] and is shown in Fig. 1. Patients with
intermediate coronary arterial lesions who presented with signs
or symptoms suggestive of myocardial ischemia and who qual-
ified for the study based on enrollment criteria were included
either from the cardiac catheterization laboratory or from the
cardiovascular computed tomography laboratory. Main inclu-
sion criteria included the following: adults ages 18–70, no
known or prior CAD, symptoms suggestive of myocardial
ischemia or high likelihood of CAD, and at least one “interme-
diate” coronary lesion (40–70 % percent diameter stenosis
based on CTA or XRA). All patients underwent invasive coro-
nary angiography (XRA) with quantitative coronary angiogra-
phy (QCA), fractional flow reserve (FFR) measurements,
intravascular ultrasound (IVUS) with radiofrequency backscat-
ter analysis (IVUS/VH), and multi-detector computed tomogra-
phy (MDCT) coronary angiography (CTA) at baseline. A
“study lesion” was prospectively identified in each patient,
which was quantitatively evaluated by CTA, IVUS/VH, and
FFR measurements. Patients were contacted 6 and 12 months
after the baseline evaluation for follow-up and returned at 1 year
for repeat CTA examination. The 6- and 12-month follow-up
visits were conducted through telephone interviews.
Study Endpoints, Event Definitions, and Adjudication
Process
The primary endpoint of the overall study was an agreement
between CTA and IVUS/VH for quantitative measurements of
coronary plaque and stenosis and has been published elsewhere
[15]. Therefore, sample size calculation was predicated on the
number of patients required to assess the agreement between
CTA- and IVUS/VH-derived quantitative measurements of
plaque. Although the study was not powered to predict cardio-
vascular events, we prospectively collected MACE in a pre-
specified manner. Pre-specified components of MACE included
death from any cause, myocardial infarction (MI), target lesion
Fig. 1 ATLANTA study design. Patients with intermediate lesions (40–
70 %) were recruited based on XRA or CTA; each pre-specified study
lesion underwent IVUS/VH and FFR. CTA was repeated at 12 months.
CTA computed tomography angiography, XRA invasive X-ray coronary
angiography, QCA quantitative coronary angiography, FFR fractional
flow reserve, IVUS intravascular ultrasound, VH virtual histology
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revascularization (TLR), and ischemia distal to the study lesion,
in a hierarchal fashion. For example, if a patient had ischemia in
the territory of the study lesion that resulted in TLR, this event
was only accounted for as TLR and not as TLR and ischemia.
MI was defined using standard AHA/ACC definitions and
included both ST-segment elevation and non-ST-segment
elevation MI [17]. TLR was defined as either percutaneous
coronary intervention (PCI) of the study lesion or coronary
artery bypass grafting (CABG) that bypassed the study lesion.
Myocardial ischemia was defined as reversible perfusion defect
on radionuclide myocardial perfusion imaging, vasodilator
stress cardiovascular magnetic resonance examination, or
stress-induced wall motion abnormality on stress echocardiog-
raphy. The AHA/ASNC 17-segment model was used to assign
myocardial territories to each study lesion [18].
Each component of MACE was carefully assessed during
the 6- and 12-month interviews with patients using a pro-
spectively designed, structured questionnaire, addressing
each component of the pre-specified MACE endpoint. In
addition, all hospitalization records, cardiovascular proce-
dural records, and interim office-visit records were reviewed
to ensure adequate follow-up information. All cardiac cath-
eterization images were reviewed in patients who underwent
PCI or CABG during the follow-up to determine whether
the study lesion was indeed revascularized. Patients who
could not be contacted and who did not respond were
checked against the Social Security Death Index (SSDI).
Once all information regarding cardiovascular outcomes
was collected, each prospective event was carefully adjudicated
by two cardiologists independently (S.V. and S.R.), and
disagreement was resolved by consensus.
IVUS-VH Image Acquisition
After intracoronary injection of nitroglycerin (mean total
dose per case, 561.5 mcg; range, 0–1,800 mcg) and after
placing a guiding catheter in the target coronary artery, a
3.2-F, 20-mHz ultrasound catheter (Eagle Eye; Volcano Inc.;
Rancho Cordova, CA, USA) was inserted and was advanced
at least 2 cm beyond the most distal portion of the target
lesion. Automated pullback was performed at a rate of
0.5 mm/s (R-100; Volcano Inc.; Rancho Cordova, CA,
USA). The electrocardiographic signal was simultaneously
recorded for the reconstruction of the radiofrequency back-
scatter information using In-Vision Gold (Volcano Inc.;
Rancho Cordova, CA, USA).
IVUS/VH Image Analysis
De-identified IVUS/VH datasets were analyzed by an experi-
enced cardiologist (G.V.) using dedicated software (pcVH
3.0.394, Volcano Inc., Rancho Cordova, CA, USA) on a
dedicated workstation. Semi-automatic contouring of the lu-
minal boundary and the external elastic lamina was performed
in each frame. For plaque geometrical parameters, plaque
burden was calculated as the difference between the vessel
area and the luminal area expressed as a percentage of the
vessel area (Fig. 2). Based on a previously validated algorithm
[14], the software classified each pixel as dense calcium (DC;
white color), fibrous tissue (FI; green color), fibrofatty tissue
(FF; light green color), and necrotic core (NC; red color;
Fig. 3). Total volume and percentage of each of the four
components was measured in the study segment. Furthermore,
we calculated the volume and percent of all non-calcified
plaque components (sum of NC, FF, and FI).
Each study lesion was evaluated both in a two-dimensional
(2D) and 3D fashion. Plaque classification was performed
based on the plaque composition and geometrical analysis
by IVUS/VH. Each plaque was characterized based on accept-
ed IVUS/VH phenotypes such as pathological intimal thick-
ening (PIT), thick-cap fibroatheroma (ThCFA), and TCFA
[14, 19]. PIT was defined as the presence of predominantly
Fig. 2 The figure represents
the schematic for calculation of
plaque burden for 2D study
segment. 2D bi-dimensional,
EEL external elastic lamina,
IEL internal elastic lamina, V
vessel area, L lumen area
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FI and FF tissue with ≤10 % of NC, ≤10 % of DC, and
with a plaque burden ≥40 % in three consecutive frames.
Fibroatheroma lesion was determined by a plaque burden
≥40 % with a NC ≥10 % in three consecutive frames. The
fibroatheroma lesions were classified based on the presence
(VH-ThCFA) or absence (VH-TCFA) of a fibrous cap
(Fig. 4a–c).
2D analysis 2D analysis was predicated on the site of the
minimal luminal area (MLA). Plaque geometrical parame-
ters [minimal luminal diameter (MLD), MLA, and plaque
burden] were measured in the MLA frame, as well as in a
frame proximal and distal to the MLA, and values from
these three consecutive frames were averaged. Similarly,
area and percentage of each plaque component was measured
in the same three consecutive frames and were averaged
between these frames (Fig. 5a).
3D analysis In addition to the 2D analysis, we also measured
plaque geometrical and compositional parameters in each dis-
tinct plaque within the region of the entire IVUS/VH pullback.
The entire vessel pullback from the IVUS/VH dataset was
analyzed frame-by-frame in each subject, and the MLA frame
was identified. The study segment was extended proximally
and distally from the MLA frame until three consecutive
frames had less than 40 % plaque burden (Fig. 5b). Absolute
total plaque volume was measured in each plaque, as well as
the volume and percent of each of the four plaque components.
Plaque burden was also calculated in 3D in the entire plaque as
the difference between the vessel volume and the luminal
volume expressed as a percentage of the vessel volume.
Statistical Methods
Normally distributed continuous variables are expressed as
mean±SD, and non-normally distributed variables as median
(inter-quartile range). Normality of distribution was assessed
by the Kolmogorov–Smirnoff test. Clinical features and
IVUS/VH-derived plaque geometrical and compositional pa-
rameters were compared between patients with and without
MACE using two-sided, unpaired Student's t test for variables
with normal distribution, with Kruskal–Wallis one-way anal-
ysis of variance for non-normally distributed variables and
with the Fischer exact test for categorical data sets. A p value
of 0.05 or less was considered statistically significant. Vari-
ables that were significant in univariate analysis were entered
in a multivariable stepwise logistic regression model.
Fig. 3 Plaque composition by intravascular ultrasound with
radiofrequency backscatter analysis (IVUS/VH). IVUS/VH segment is
shown in the entire longitudinal section (a) and in cross-section at the
minimal luminal area (MLA) frame (b)
Fig. 4 Morphological lesion subtypes identified by intravascular
ultrasound with radiofrequency backscatter analysis (IVUS/VH).
Three plaque subtypes are shown: (a) pathological intimal thickening
(PIT), (b) thick-cap fibroatheroma (VH-ThCFA), and (c) thin-cap
fibroatheroma (VH-TCFA)
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Results
General Demographics
Sixty patients were enrolled in the study; general demo-
graphic characteristics are shown in Table 1. Mean age
was 60.4±7.2 years, and 60 % were men. Mean 10-year
Framingham risk score in the study population was 8.4±
6.0 %. The presence of hypertension, diabetes, dyslipidemia,
tobacco use, and lipoprotein levels were representative for a
population with no prior CAD presenting with signs and
symptoms of myocardial ischemia (Table 1).
Major Adverse Cardiovascular Events (MACE)
At the end of the pre-specified 12-month follow-up, a total
of five patients (8.3 %) had an adjudicated MACE. The five
patients in the MACE group presented with unstable angina.
There was no death or myocardial infarction. All the five
MACE were in the form of target lesion revascularization;
four patients (6.7 %) had PCI, and one patient (1.7 %) had
CABG. Median time to event was 72 days. IVUS/VH data
was not available in one patient in the MACE group.
Clinical Parameters and FFR
TheMACE and the no-MACE groups were similar with respect
to age, presence of hypertension, diabetes, dyslipidemia, and
tobacco use. Lipoprotein parameters were also similar between
the groups (Table 2). Lesions associated withMACEwere non-
flow-limiting and were not different from lesions with no
MACE; mean FFR in the no-MACE group was 0.89 and in
the MACE group was 0.90 (p=0.7).
IVUS/VH Parameters in the Overall Population
IVUS/VH Parameters: 2D Analysis
Geometry Geometrical parameters [MLD, MLA, percent-
age of area stenosis (%AS), and percentage of diameter
stenosis (%DS)] were not different between the groups by
IVUS/VH analysis (Table 3).
Fig. 5 Schematic
representation of 2D and 3D
IVUS/VH analysis. For the 2D-
IVUS/VH analysis, plaque
geometrical parameters (MLD,
MLA, and plaque burden) were
measured in the MLA frame as
well as in a frame proximal and
distal to the MLA, and the
values from these three
consecutive frames were
averaged (a). For the 3D-IVUS/
VH analysis, in each subject,
the entire vessel pullback from
the IVUS/VH dataset was
analyzed frame-by-frame, and
the MLA frame was identified.
The study segment was
extended proximally and
distally from the MLA frame
until three consecutive frames
had less than 40 % plaque
burden (b). 2D bi-dimensional,
3D three-dimensional, IVUS
intravascular ultrasound, VH
virtual histology, MLA minimal
lumen area
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Composition 2D analysis showed significantly higher
plaque area in lesions associated with MACE compared to
those without MACE (12.5±8.3 vs. 7.9±3.5 mm2, p=0.04).
DC percentage was lower in the MACE group (2.5±0.3 %
vs. 13.4±9.4 %, p=0.03), while FF area and percentage
were higher (2.9±1.7 vs. 0.8±1.0 mm2, p<0.001, and
34.2±15.9 % vs. 12.5±10.2 %, p<0.001, respectively).
Other compositional parameters were comparable in the
two groups (Table 4 and Fig. 6). Plaque type was character-
ized as VH-TCFA in all five patients with MACE, while only
32 of 47 patients (69 %) in the no-MACE group had this
lesion type (p=0.42). Other lesion subtypes in the no-MACE
group were VH-ThCFA (29 %) and PIT (2 %).
IVUS/VH Parameters: 3D Analysis
Geometry There were no differences in MLD and MLA by
IVUS/VH between the MACE and no-MACE groups
(Table 5).
Composition Lesions associated with MACE had signifi-
cantly larger plaque burden as compared to lesions not
associated with MACE (65.1±5.1 % vs. 53.0±7.8 %, p=
0.004). FF volume and percentage were significantly
higher in the MACE group as compared to the no-MACE
group (44.1±30.3 vs. 20.7±15.9 mm3, p=0.01, and 17.6±
12.7 % vs. 10.0±5.6 %, p=0.02, respectively). The MACE
group had a proportionally higher amount of non-calcified
plaque (NCP; 93.6±3.5 % vs. 86.0±7.8 %, p=0.05). Con-
versely, the percentage of DC was lower in MACE-
associated lesions (6.4±3.5 % vs. 14.0±7.8 %, p=0.05).
Results are shown in Table 6 and illustrated in Fig. 6
(bottom row).
Multivariable Analysis
Clinical features and IVUS-VH plaque characteristics
were tested in a multivariable stepwise logistic regression
model that included age, gender, presence of diabetes,
lipoprotein parameters, and the geometrical and compo-
sitional plaque parameters as independent variables and
MACE as the dependent variable. Only fibrofatty volume
was retained as an independent variable with an odds
ratio of 1.058 for MACE (95 % confidence interval,
1.004 to 1.115, p=0.03).
Discussion
There are two significant novel aspects of the present study.
First, this is one of a few studies that prospectively com-
pared coronary plaque characteristics using IVUS/VH in








Age (years) 60.4±7.2 58.4±6.6 60.6±7.3 0.5
Men, % 60 % 60 % 60 % 1
Ethnicity
Caucasians 92 % 100 % 91 % 1
African-Americans 8 % 0 % 9 %
Risk factors
Hypertension 83 % 80 % 84 % 1
Dyslipidemia 95 % 100 % 95 % 1
Tobacco use 58 % 60 % 58 % 1
Diabetes 73 % 80 % 73 % 1
Framingham risk score
(10-year risk)
8.5±6.0 10.2±9.9 8.3±5.6 0.5
Symptoms
Chest pain 45 % 60 % 44 % 1
Shortness of breath 10 % 0 % 11 % 1
Medications
Aspirin 71 % 100 % 69 % 0.3
Beta-blockers 51 % 40 % 52 % 0.7
ACE inhibitor 31 % 40 % 30 % 0.6
ARB 10 % 20 % 9 % 0.4
Nitrate 10 % 40 % 7 % 0.08
Statin 68 % 40 % 70 % 0.3
Cholesterol absorption
inhibitors
25 % 0 % 28 % 0.3
Niacin 15 % 20 % 15 % 0.6
Fibric acid derivatives 5 % 0 % 6 % 1
Normally distribute variables, mean±SD
MACE major adverse cardiac events, SD standard deviation




Characteristic All (N=60) MACE (N=5) No MACE (N=55) p value
Laboratory values
TC (mg/dL) 155.0±43.3 166.0±14.9 154.0±45.0 0.6
ApoB (mg/dl) 78.1±27.5 86.8±15.4 77.3±28.4 0.5
LDL-C (mg/dl) 84.7±35.7 97.1±19.4 83.5±36.7 0.4
ApoAI (mg/dl) 144.9±30.1 154.5±35.6 144.0±29.8 0.5
HDL-C 38.3±12.1 39.2±10.9 38.2±12.6 0.9
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patients with MACE versus those without MACE over a 12-
month period. Secondly, in addition to a cross-sectional
analysis at the MLA site, we also used a detailed, 3D
quantitative characterization of each plaque within the region
of the IVUS pullback, providing more insight into the overall
features of those plaques.
The present study has five important findings. First, as
expected, event rate associated with intermediate lesions
was low; only 5 of 60 plaques (8.3 %) were responsible
for MACE over a 12-month period. Secondly, FFR was
similar in plaques with and without MACE. Thirdly, as
previously reported in PROSPECT [16] and VIVA [20],
lesions associated with MACE had significantly more
plaque, as evidenced by higher plaque area at the MLA site
and higher plaque burden in the entire plaque. Fourthly,
plaque composition in MACE lesions was shifted toward
less calcified and more non-calcified components, as
evidenced by less dense calcium both at the MLA site as
well as in the entire plaque. Finally, a unique and novel
finding was the higher amount and percentage of fibrofatty
tissue both at the MLA site as well as in the entire plaque.
Importantly, all five MACE lesions were characterized as
VH-TCFA compared to only 69 % of non-MACE plaques,
although this was not statistically significant.
The progression of atherosclerosis follows a reasonably
predictable course [22] through some distinct phases and
characteristic phenotypes and several features can be
detected by IVUS/VH [21, 23]. Growth in coronary plaque
size initially occurs in an outward fashion with preservation
of the luminal size; this process is called “positive” remodel-
ing and was initially described by Glagov [24] and presents an
excellent target for atherosclerosis imaging by IVUS/VH [25].
This stage of positive remodeling is followed by continued
phagocytosis by macrophages leading to development of a
necrotic core and subsequent formation of TCFAs [6, 9].
While IVUS/VH is able to accurately detect and quantify
necrotic core in human coronary arterial plaques [21], its
resolution is not high enough to measure the thickness of the
fibrous cap; however, an IVUS/VH definition of TCFA has
been devised and is referred to as VH-TCFA [15, 26] (Fig. 5).
Ruptured TCFAs are thought to be one of the most important
underlying causes of sudden cardiac death and ACSs [6, 8].
Calcification, which occurs as part of the healing process in
large, positively remodeled plaques that undergo repeated,
spontaneous intra-plaque hemorrhage without leading to
ACS [27], is also an easy target for IVUS/VH imaging [28,
29]. Finally, the latest stages of the atherosclerotic process are
characterized by further calcification and fibrosis, severe lu-
minal stenosis, and negative remodeling and can also be easily
detected by IVUS/VH.
In the context of this atherosclerosis paradigm, our study
showed that MACE lesions had similar lumen size and FFR
compared to non-MACE lesions, while they were charac-
terized by larger plaque burden with more non-calcified
plaque, especially the fibrofatty kind, with significantly less
calcium. Furthermore, all five of MACE lesions were char-
acterized as VH-TCFA. Therefore, our study is consistent
with histopathological studies of coronary atherosclerosis.
Our findings are also consistent with previous imaging
studies and expand on those findings. With regards to event
rates, a large meta-analysis by Nicholls et al. demonstrated
that MACE rate associated with non-obstructive lesions,
similar to our study, was approximately 11 % per year,
similar to the 8.3 % found in our study [30]. The results of
the large, prospective PROSPECT study have been pub-
lished showing an annualized event rate of 6.9 % in inter-
mediate coronary lesions, similar to our study [16].
It is not surprising that in the present study FFR was not
different between groups since we only included intermedi-
ate lesions. It is well known that with the inclusion of the
entire spectrum of intermediate-to-severe stenosis, FFR has
significant prognostic value [31].
Table 3 2D IVUS/VH geometrical plaque differences between MACE






MLD 1.78±0.46 1.96±0.48 0.5
MLA 3.62±1.52 4.12±2.12 0.6
%AS 46.8±22.4 52.7±15.8 0.5
%DS 26.0±20.29 31.6±11.52 0.4
Normally distribute variables, mean±SD
IVUS intravascular ultrasound, VH virtual histology, MLD minimal
lumen diameter, MLA minimal lumen area, %AS percentage area
stenosis, %DS percentage diameter stenosis, MACE major adverse
cardiac events, SD standard deviation
Table 4 2D IVUS/VH compositional plaque differences between








Plaque area 12.5±8.3 7.9±3.5 0.04
FI area 4.8±4.2 2.7±1.7 0.5
FF area 2.9±1.7 0.8±0.9 <0.001
NC area 1.7±1.9 1.3±1.0 0.5
DC area 0.2±0.2 0.7±0.6 0.2
FI, % 47.9±7.0 51.1±13.9 0.7
FF, % 34.2±15.9 12.5±10.2 <0.001
NC, % 15.4±9.3 23.0±10.5 0.2
DC, % 2.5±0.3 13.4±9.4 0.03
Normally distribute variables, mean±SD
2D bi-dimensional, IVUS intravascular ultrasound, VH virtual histolo-
gy, MACE major adverse cardiac events, SD standard deviation, FI
fibrous, FF fibrofatty, NC necrotic core, DC dense calcium
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Previous IVUS-based studies also showed that MACE le-
sions were associated with larger plaque burden and relatively
preserved luminal size [30–32].
Results from PROSPECT, a large, prospective, landmark
study using three-vessel IVUS/VH in approximately 700 pa-
tients with ACS followed for a median of 3.4 years, showed
that MLA<4 mm2 [hazard ratio (HR), 3.21, p=0.001), plaque
burden 70% (HR, 5.03, p<0.001) or greater, and the presence
of VH-TCFA (3.35, p<0.001) were independent predictors of
MACE. Results from VIVA, an additional large prospective
study using three-vessel IVUS/VH in 170 patients with stable
angina and ACS followed for 1.9 years, demonstrated that
MLA<4 mm2 (HR, 2.91, p=0.036), plaque burden>70 %
(HR, 7.48, p=0.001), and VH-TCFA (HR, 8.16, p=0.007)
were associated with MACE; our findings are largely consistent
with these findings [16, 20].
We also found that MACE lesions had more non-
calcified plaque and less calcified components. This is
consistent with histopathological findings, which showed
that ACS lesions were associated with less calcification
compared to stable lesions [11, 12]. These findings are
also consistent with those by Yamagishi et al. [32] and
Sano et al. [33], who also found more lipid-rich plaque
and more echolucent plaque in culprit lesions, compared
to non-culprit lesions.
One relatively unexpected, and previously unreported,
finding in our study was the difference in fibrofatty tissue
volume and percentage between MACE and non-MACE
Fig. 6 Significant predictors of MACE via the two-dimensional (2D; top row) and three-dimensional (3D; bottom row) IVUS/VH analyses.MACE
major adverse cardiac events, 2D bi-dimensional, 3D three-dimensional, IVUS intravascular ultrasound, VH virtual histology
Table 5 3D IVUS/VH geometrical plaque differences between MACE








MLD 1.78±0.46 1.96±0.48 0.5
MLA 3.62±1.52 4.12±2.12 0.6
%AS 46.8±22.4 52.7±15.8 0.5
%DS 26.0±20.29 31.6±11.52 0.4
RI 88.0±1.8 88.6±9.9 0.9
Normally distribute variables, mean±SD
3D three-dimensional, IVUS intravascular ultrasound, VH virtual his-
tology, MLD minimal lumen diameter, MLA minimal lumen area, %AS
percentage area stenosis, %DS percentage diameter stenosis, MACE
major adverse cardiac events, RI remodeling index, SD standard
deviation
Table 6 3D IVUS/VH compositional plaque differences between








Plaque burden (%) 65.1±5.1 53.0±7.8 0.004
FI volume 133.0±74.0 106.0±70.6 0.5
FF volume 44.1±30.3 20.7±15.9 0.01
NC volume 51.8±32.1 54.2±36.0 0.9
DC volume 17.3±14.2 31.0±27.5 0.3
FI, % 54.6±8.1 51.0±10.0 0.5
FF, % 17.6±12.7 10.0±5.6 0.02
NC, % 21.3±7.1 25.0±6.5 0.3
DC, % 6.4±3.5 14.0±7.8 0.05
NCP, % 93.6±3.5 86.0±7.8 0.05
All volumes are in cubic millimeters
3D three-dimensional, IVUS intravascular ultrasound, VH virtual his-
tology, MACE major adverse cardiac events, SD standard deviation, FI
fibrous, FF fibrofatty, NC necrotic core, DC dense calcium, NCP non-
calcified plaque
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lesions, both at the MLA site, as well as in the entire plaque.
Interestingly, in the multivariable analysis, this was the only
feature that retained independent significance. Relatively
little data is available with regards to fibrofatty tissue
on IVUS/VH. Histopathologically, it probably represents
slightly earlier-stage, lipid-rich plaques prior to the devel-
opment of a necrotic core. The fact that our study was a
lower-risk population compared to some of the previous
studies described above, which mostly enrolled patients
with ACS, while our study population was not an ACS
population may be a potential explanation for this finding.
Furthermore, it has been suggested that thrombi may be
identified as fibrofatty tissue on IVUS/VH [34]; however,
careful review of our cases did not identify thrombus in
these cases.
This study adds to the current literature on the predic-
tive value of IVUS/VH for the prospective identification
of potential lesions that may be associated with MACE
in the future.
Limitations
There are several limitations to our study. Most importantly,
it was a single-center study with a relatively low sample
size. As it was described above, the primary endpoint of the
overall study was the agreement between IVUS/VH and
coronary CTA for percent atheroma volume, and sample
size calculation was designed to fulfill that primary end-
point. Therefore, the study was not powered for the detec-
tion of MACE. Nevertheless, we did collect pre-specified
MACE events in the study, all events were adjudicated by
two cardiologists, and the statistical analysis revealed sig-
nificant differences between MACE and non-MACE le-
sions, despite the low overall sample size. In addition, as a
consequence of the lower number of patients in the MACE
group, the multivariable analysis is limited. As a result, the
data generated in this study should only be hypothesis
generating. Secondly, the follow-up period of 12 months
was relatively short, although this time-point is customary
for the follow-up of MACE in large clinical trials. Thirdly,
we only evaluated one vessel in each patient by IVUS/VH.
Finally, we did not perform serial IVUS/VH imaging; it was
only performed at baseline. Other modalities, such as coro-
nary CTA, may be better positioned for serial imaging, as
the dropout rate in serial IVUS studies is approximately 30–
40 % [35].
Conclusions
In conclusion, our study found that while major cardiovascular
event rates were low due to non-flow-limiting, intermediate
coronary arterial lesions, MACE lesions by IVUS/VH overall
had larger plaque burden due to more non-calcified plaque
components, mostly due to fibrofatty tissue and less calcified
components. All lesions associated with MACE within a 12-
month follow-up were characterized as VH-TCFA at baseline.
Understanding the natural history of non-flow-limiting coro-
nary arterial lesions will aid in designing pre-emptive strategies
to combat vulnerable plaques, and such strategies will have to
be tested in large-scale, multi-center clinical outcome trials.
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